$107,530,978
to ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
THIS CONTRACT WILL SUPPORT COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES, BASED ON PRINCIPLES OF INFLUENZA IMMUNITY, THAT ACHIEVE DURABLE, ROBUST
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Latest obligation on a 2019 NIH grant supporting Mount Sinai's work designing next-generation influenza vaccines through the CIVICS program.
Influenza vaccine innovation directly addresses pandemic preparedness and seasonal flu burden; durable, broadly protective vaccines could reduce annual mortality and healthcare costs.
Advances in vaccine platform technology may influence downstream manufacturing capacity and clinical trial infrastructure for rapid vaccine deployment.
U.S. investment in next-generation vaccine platforms competes with international efforts to develop superior influenza countermeasures and establish vaccine technology leadership.
Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-27. Cost: $0.002992.
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier CONT_AWD_75N93019C00051_7529_-NONE-_-NONE-.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.